COMMUNIQUÉS West-GlobeNewswire

RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue
21/01/2025
First-in-class, steroid-free compound reduced inflammatory and fibrotic biomarkers in human lung tissue furthering support as a new advancement in the treatment of deadly lung diseases CUMBERLAND, Md., Jan. 21, 2025 ( [...]
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025
21/01/2025
PALO ALTO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid [...]
Cell BioEngines Announces Establishment of New R&D Facility to Further Advance Its Platform and Pipeline of Innovative Cell Therapies
21/01/2025
Cell BioEngines Joins Center for Engineering and Precision Medicine (CEPM), Expands Relationship with Mount Sinai NEW YORK, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Cell BioEngines, Inc. (“Cell BioEngines” or the “Company”), a [...]
Neoviva est la première clinique suisse de traitement des dépendances à offir une garantie
21/01/2025
LUCERNE, Suisse, 21 janv. 2025 (GLOBE NEWSWIRE) -- Neoviva, un centre de réadaptation de luxe de premier plan, lance le premier et unique programme de garantie en matière de traitement des dépendances en Suisse. Doté d’ [...]
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
21/01/2025
ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor [...]
Harris Health Partners With Capsa Healthcare To Triple Capacity In Its Central Fill Pharmacy Operations
21/01/2025
COLUMBUS, Ohio, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Capsa Healthcare, a leader in advanced healthcare workflow solutions, announced today that Houston, TX-based Harris Health has chosen Capsa as its design and [...]
Coloplast A/S - Q1 2024/25 Earnings Release - Invitation to conference call on 4 February 2025 at 11.00am CET
21/01/2025
Tuesday, 4 February 2025 at 10.00 - 11.00am CET In connection with the publication of Coloplast’s interim financial results for Q1 2024/25, to be released same day around 07.30am CET, Coloplast will host a conference [...]
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
21/01/2025
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis ® ) with the potential to [...]
Yerbae Expands Midwest Convenience Store Presence with Casey's General Stores Authorization
21/01/2025
SCOTTSDALE, Ariz., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Yerbaé Brands Corp. (TSX-V: YERB.U; OTCQX: YERBF) (“Yerbaé” or the “Company”), a plant-based functional beverage company, today announced a significant expansion of [...]
Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC
21/01/2025
PALO ALTO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid [...]
Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa
21/01/2025
FORT WORTH, Texas, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Nacuity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for retinitis pigmentosa, cataracts and other diseases caused by [...]
Olympia Pharmaceuticals Expands into Alabama with New Licensing, Bringing GLP-1s and More to Healthcare Providers
21/01/2025
Nation’s leading compound pharmacy is now available in 48 states ORLANDO, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Olympia Pharmaceuticals , a state-of-the-art, FDA-registered 503B pharmaceutical outsourcing facility, is [...]
Welcoming Victor Bornsztejn as Senior Vice President of Commercial
21/01/2025
SAN FRANCISCO, CALIFORNIA, UNITED STATES, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Culture Biosciences, a leader in cloud-connected bioprocessing technologies, is pleased to announce the appointment of Victor Bornsztejn as the [...]
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
21/01/2025
GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving [...]
Completion of Offering and Increase in Registered Capital
21/01/2025
TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO [...]
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
21/01/2025
- Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation - CHARLESTOWN, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. ( [...]
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
21/01/2025
Study showed online screening tool and patient education improved genetic testing completion rate SALT LAKE CITY, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc . (NASDAQ: MYGN), a leader in genetic testing and [...]
Bluejay Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Brelovitug (BJT-778) for the Treatment of Chronic Hepatitis Delta
21/01/2025
Breakthrough Therapy Designation is designed to expedite the development and review of therapies that may show significant improvement over available treatments for serious conditions REDWOOD CITY, Calif., Jan. 21, 2025 [...]
Adaptive Research Expands into Psychiatry with Addition of Prodigy Psychiatric Group to Clinical Trial Network
21/01/2025
SAN FRANCISCO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adaptive Research Inc. announced that Prodigy Psychiatric Group has joined its clinical trial network, marking Adaptive Research's expansion into psychiatric research. [...]

Pages